Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 6,920 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 6,920 shares of the firm’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $31.44, for a total value of $217,564.80. Following the transaction, the senior vice president directly owned 143,271 shares in the company, valued at approximately $4,504,440.24. This represents a 4.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, October 6th, Paula Green sold 9,724 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total value of $313,015.56.
• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The stock was sold at an average price of $27.56, for a total value of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The shares were sold at an average price of $25.76, for a total value of $22,977.92.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.57 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The business has a 50 day simple moving average of $29.05 and a 200-day simple moving average of $31.79. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The stock has a market capitalization of $1.91 billion, a PE ratio of -21.77 and a beta of 2.43.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of the company. AlphaQuest LLC raised its holdings in Twist Bioscience by 202.6% during the third quarter. AlphaQuest LLC now owns 22,555 shares of the company’s stock worth $635,000 after purchasing an additional 15,101 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in shares of Twist Bioscience by 2.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,122 shares of the company’s stock valued at $651,000 after buying an additional 628 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of Twist Bioscience by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after buying an additional 71,777 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of Twist Bioscience by 62.8% in the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock worth $35,533,000 after buying an additional 487,052 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Twist Bioscience by 822.2% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 65,590 shares of the company’s stock valued at $1,846,000 after acquiring an additional 58,478 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently weighed in on TWST shares. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Stephens assumed coverage on Twist Bioscience in a report on Monday. They issued an “overweight” rating and a $41.00 price objective on the stock. Evercore ISI cut their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Finally, Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $47.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.